{"commentary":{"count":9,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":5,"youtube":3,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01992952\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"FAKTION","nct_id":"NCT01992952","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=faktion-nct01992952. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"FAKTION","arms":[{"description":"Fulvestrant 500mg and AZD5363 4 days on 3 days off at dose determined in safety run in (maximum 480mg and minimum 320mg bd)","label":"AZD5363 plus fulvestrant","type":"EXPERIMENTAL"},{"description":"Fulvestrant 500mg D1, D15 (cycle 1) and D1 of a 28 cycle thereafter. AZD5363 placebo 4 days on 3 days off","label":"Placebo plus fulvestrant","type":"ACTIVE_COMPARATOR"}],"collaborators":["AstraZeneca","Cenduit LLC","Covance","Cardiff and Vale University Health Board"],"completion_date":{"date":"2025-12-31","type":"ESTIMATED"},"conditions":["Estrogen Receptor Positive Breast Cancer"],"enrollment":{"count":149,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"AZD5363","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Fulvestrant","type":"DRUG"}],"last_update":"2025-11-26","lead_sponsor":"Velindre NHS Trust","official_title":"A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2019-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phase 1b primary outcome measure: Maximum Tolerated Dose of AZD5363 in combination with fulvestrant","timeFrame":"6 months"},{"measure":"Phase 2 primary outcome: Progression free survival (PFS)","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months after the last patient is randomised"}],"references":[{"citation":"Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, Meissner M, Bale C, Bezecny P, Moon S, Twelves C, Venkitaraman R, Waters S, de Bruin EC, Schiavon G, Foxley A, Jones RH. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 2022 Jul;23(7):851-864. doi: 10.1016/S1470-2045(22)00284-4. Epub 2022 Jun 4.","pmid":"35671774","type":"DERIVED"},{"citation":"Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2020 Mar;21(3):345-357. doi: 10.1016/S1470-2045(19)30817-4. Epub 2020 Feb 5.","pmid":"32035020","type":"DERIVED"}],"start_date":{"date":"2014-05-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer","url":"https://clinicaltrials.gov/study/NCT01992952"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/faktion-nct01992952"}